[1] FAN X S,CHEN J Y,LI C F,et al.Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population[J].World J Gastroenterol,2013,9(21):3316-3323.
[2] LAMBEIN K,VAN BOCKSTAL M,VANDEMAELE L,et al.Distinguishing score 0 from score1+in HER2 immunohisto-chemistry-negative breast cancer:clinical and pathobiological relevance[J].Am J Clin Pathol,2013,140(4):561-566.
[3] 刘晓伟,张宏.HER2蛋白在胃癌组织中的表达及其临床研究[J].内蒙古医科大学学报,2018,40(4):412-414.
[4] 明洁,逯翀,田元,等.乳腺癌HER2与TOP2A的表达及其相关性[J].解剖学报,2010,41(3):391-394.
[5] 汤彪,孙圣荣.甲状腺乳头状癌中TPO、HER-2的表达及临床意义[J].热带医学杂志,2015,15(9):1215-1218.
[6] 朱敬华,周建农.实时荧光定量RT-PCR检测结肠癌中Musashi-1 mRNA的表达[J].南京医科大学学报(自然科学版),2009,29(5):656-668.
[7] 帅萍.乳腺癌组织中HER2和TOPOⅡα的表达及其临床意义[J].中南大学学报(医学版),2016,41(11):1143-1147.
[8] SLAMON D J,GODOLPHIN W,JONES L A,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science 1989,244(1):707.
[9] 汤小江,周瑜辉,张伟,等.TOP2A基因表达与乳腺癌HER2通路的相关性[J].西安交通大学学报(医学版)2015,36(4):519-522.
[10] YOSHIYUKI M,KAZUAKI S,ISOKO K,et al.Inhibitory effects of a major soy isoflavone,genistein,on human DNA topoisomerase Ⅱ activity and cancer cell proliferation[J].International Journal of Oncology,2013,43:1117-1124.
[11] KODACK D P,CHUNG E,YAMASHITA H,et al.Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases[J].Proc Natl Acad Sci USA,2012,109(45):E3119-E3127. |